PBRM1 and nonpapillary renal cell carcinoma: PBRM1 deficiency has been identified in a number of studies as a biomarker for immunotherapy in ccRCC (Miao et al. 2018; Braun et al. 2020; Courtet et al. 2020; Dizman et al. 2020).